Investors seek answers on Novo Nordisk’s next-gen obesity drug CagriSema
By Maggie Fick and Robin Respaut LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information ...
Read moreDetailsBy Maggie Fick and Robin Respaut LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information ...
Read moreDetails
